tert-butyl 4-aminopentanoate | 790604-06-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 4-aminopentanoate
• CAS: 790604-06-7
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: WAOWMAGPPDFHBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-aminopentanoate 在 supported Candida antartica lipase B 作用下， 以 甲基叔丁基醚 、 2,2,2-三氟乙酰胺 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Chemoenzymatic Dynamic Kinetic Resolution of Primary Amines Catalyzed by CAL-B at 38–40 °C

  摘要：

  The (R)-selective chemoenzymatic dynamic kinetic resolution of primary amines was performed at 38-40 degrees C in MTBE, in good to high yields and with high enantiomeric excesses. These reactions associating CAL-B to octanethiol as radical racemizing agent were carried out in the presence of methyl beta-methoxy propanoate as acyl donor, under photochemical irradiation at 350 nm in glassware.

  DOI：

  10.1021/jo201256w

文献信息

• NOVEL HETEROCYCLYL COMPOUNDS
  申请人：Aebi Johannes

  公开号：US20110092698A1

  公开（公告）日：2011-04-21

  The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 7 , R 8 , R 9 , and R 10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

  这项发明涉及式(I)的新颖双环化合物，其中n、m、p、A、L、R1、R2、R3、R4、R5、R6、R7、R7、R8、R9和R10如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂，例如可用于预防和/或治疗炎症性疾病，特别是外周动脉闭塞疾病或动脉粥样硬化形成。
• [EN] DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS<br/>[FR] DÉRIVÉS DU DIAZÉPAM EN TANT QUE MODULATEURS DES RÉCEPTEURS DES CHIMIOKINES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011048032A1

  公开（公告）日：2011-04-28

  The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

  这项发明涉及公式（I）的新颖双环化合物，其中n、m、p、A、L、R1、R2、R3、R4、R5、R6、R7、R7、R8、R9和R10的定义如描述和索赔中所述，以及其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂，可用作药物。
• [EN] PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL) METHYL)BENZYL) AMINO)ISOINDOLINE-1,3-DIONE<br/>[FR] PROCÉDÉS DE PRÉPARATION DE (S)-2-(2,6-DIOXOPIPÉRIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZÉTIDIN-1-YL)MÉTHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
  申请人：CELGENE CORP

  公开号：WO2022271557A1

  公开（公告）日：2022-12-29

  Provided herein are processes for the preparation of (S)-2-(2,6- dioxopipelidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-l-yl) methyl) benzyl)amino)isoindoline-l, 3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, which is useful for treating, preventing, and managing various disorders. Also provided are solid forms of various intermediates and products obtained from the processes.

  本文提供了制备(S)-2-(2,6- 二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啡啉基氮杂环-1-基)甲基)苯甲基)氨基)异吲哚啉-1,3-二酮或其盐、溶剂化物、水合物、对映体、对映体混合物或同位素的方法，该化合物可用于治疗、预防和管理各种疾病。此外，还提供了从这些方法中获得的各种中间体和产物的固态形式。
• GPE analogs and peptidominetics
  申请人：——

  公开号：US20030055004A1

  公开（公告）日：2003-03-20

  This invention relates to analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic and anti-necrotic, to methods of making them, to pharmaceutical compositions containing them, and to their use.

  本发明涉及甘氨酰-L-脯氨酰-L-谷氨酸（GPE）的类似物和拟肽物。特别是，本发明涉及抗细胞凋亡和抗坏死的 GPE 类似物和拟肽物、其制造方法、含有它们的药物组合物及其用途。
• ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1040103B1

  公开（公告）日：2007-03-14